About this campaign
Looks like your text is -165 character over the limit. Please shorten it to 200 characters or less.
Looks like your text is -165 character over the limit. Please shorten it to 200 characters or less.
Looks like your text is -158 character over the limit. Please shorten it to 200 characters or less.
Looks like your text is -158 character over the limit. Please shorten it to 200 characters or less.
On September 8, 2023 our lives changed forever when our wonderful 3-year-old Juliette was diagnosed with a rare, aggressive form of brain cancer called PFA ependymoma.
Ependymoma is the third most common pediatric central nervous system (CNS) tumor, accounting for 8-10% of all diagnoses, and occurring most frequently in the posterior fossa. Unfortunately, outcomes for ependymomas are suboptimal, with overall survival of 50-64%.
The treatments for ependymoma have not changed in any significant way for decades, which is why we need a new approach.
Ependymoma Research Foundation is committed to identifying and supporting novel research projects that will lead to an effective treatment for ependymoma.
Looks like your text is -9290 character over the limit. Please shorten it to 10000 characters or less.
